Kura Oncology (KURA) Total Current Liabilities (2022 - 2026)
Kura Oncology has reported Total Current Liabilities over the past 5 years, most recently at $101.5 million for Q1 2026.
- Quarterly Total Current Liabilities rose 13.07% to $101.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $101.5 million through Mar 2026, up 13.07% year-over-year, with the annual reading at $117.0 million for FY2025, 48.61% up from the prior year.
- Total Current Liabilities was $101.5 million for Q1 2026 at Kura Oncology, down from $117.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $121.3 million in Q3 2025 and troughed at $19.2 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $37.8 million (2023), against an average of $60.8 million.
- Year-over-year, Total Current Liabilities skyrocketed 220.39% in 2025 and then increased 13.07% in 2026.
- A 5-year view of Total Current Liabilities shows it stood at $24.1 million in 2022, then soared by 46.58% to $35.3 million in 2023, then skyrocketed by 123.21% to $78.7 million in 2024, then skyrocketed by 48.61% to $117.0 million in 2025, then dropped by 13.23% to $101.5 million in 2026.
- Per Business Quant, the three most recent readings for KURA's Total Current Liabilities are $101.5 million (Q1 2026), $117.0 million (Q4 2025), and $121.3 million (Q3 2025).